Patents Assigned to Takeda Pharmaceutical Company Limited
  • Publication number: 20190241566
    Abstract: Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 8, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Takaharu HIRAYAMA, Yasuhiro HIRATA, Yusuke TOMINARI, Naoki IWAMURA, Yusuke SASAKI, Moriteru ASANO, Terufumi TAKAGI, Masanori OKANIWA, Masato YOSHIDA, Takashi ICHIKAWA, Shinichi IMAMURA
  • Patent number: 10370357
    Abstract: An object of the present invention is to provide a production method of an intermediate used in the production method of a sulfonylpyrrole compound useful as a pharmaceutical product. The present invention relates to a method of producing sulfonylpyrrole compound (VI) by reacting a pyridine-3-sulfonic acid compound with phosphorus pentachloride in a solvent of chlorobenzene or trifluoromethylbenzene to give a pyridine-3-sulfonyl chloride compound, reacting the compound without isolation with compound (III) to give compound (IV), and subjecting the compound (IV) to a reductive amination reaction. wherein R2 is a hydrocarbon group etc. and R3 and R4 are each a hydrogen atom etc., wherein R2 is an optionally substituted pyridin-3-yl group, and the other symbols are as defined above, wherein R5 is an alkyl group and the other symbols are as defined above.
    Type: Grant
    Filed: February 19, 2018
    Date of Patent: August 6, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: Keisuke Majima
  • Publication number: 20190233370
    Abstract: The present invention provides a compound having a superior Toll-like receptor 4 (TLR4) signaling inhibitory action, which may be useful as a prophylactic or therapeutic drug for diseases such as autoimmune diseases and/or inflammatory diseases, or chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver failure, and ischemia reperfusion injury (IRI). The present invention relates to ethyl 6-((2-chloro-4-fluorobenzyl)sulfonyl)-3-hydroxycyclohex-1-ene-1-carboxylate or an optical isomer thereof.
    Type: Application
    Filed: September 7, 2017
    Publication date: August 1, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake KOBAYASHI, Morihisa SAITOH, Yasufumi WADA, Nobuyuki NEGORO, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Patent number: 10357618
    Abstract: A injection-needle cover includes an injection needle enclosure portion, which has paired base-side wall portions, a cylinder portion, paired tip-end-side wall portions, an injection needle contact portion, a hook portion, and a needle tip end fixing portion. The injection needle contact portion is disposed at a position in a base-side axial space, which is a boundary between the base-side axial space and an intra-cylinder space. The injection needle contact portion has a force receiving portion and a connecting portion. The force receiving portion receives a force from the injection needle when the force receiving portion comes in contact with the injection needle. The force receiving portion has an easy sliding portion, which is disposed in an area adjacent to an injection needle, and slides more easily along the injection needle than a case where an edge slides along the injection needle.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: July 23, 2019
    Assignees: TAKEDA PHARMACEUTICAL COMPANY LIMITED, YOSHINO KOGYOSHO CO., LTD., ARTE CORPORATION
    Inventors: Kiyoshi Okajima, Yuki Imanishi, Naoki Asakawa, Nobuo Tanaka, Yusuke Chuma
  • Patent number: 10357484
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 23, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Masashi Toyofuku, Kousuke Hidaka
  • Patent number: 10350170
    Abstract: Provided is a solid preparation showing improved stability of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea and a salt thereof in the solid preparation, and a method of stabilizing the compound in a solid preparation. A tablet containing not less than 25 mass % of the compound; a solid preparation containing (1) the compound, and (2) a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate; a method of stabilizing the compound in a tablet, including adding not less than 25 mass % of the compound; and a method of stabilizing the compound, including adding a fat and oil-like substance having a low melting point, which is selected from polyethylene glycol, glycerol monostearate and triethyl citrate to a solid preparation containing the compound.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: July 16, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Ikuro Yamane, Yukihiro Nomura, Yutaka Nishimoto, Wataru Hoshina
  • Patent number: 10351618
    Abstract: The present invention provides UTI fusion proteins, DNA sequences for producing the same, and pharmaceutical compositions and methods of using the same.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: July 16, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Aaron Chamberlain, Qiang Liu, Mathias Schmidt
  • Publication number: 20190202883
    Abstract: The present invention relates to a peptide compound that may be useful in the treatment or prophylaxis of obesity, diabetes and the like. More specifically, the present invention relates to a peptide compound represented by the formula (I): P1-Tyr-Aib-Glu-Gly-Thr-?-MePhe-Thr-Ser-Asp-Lys(-Gly-Gly-Gly-Gly-RA10)-A11-A12-Aib-Leu-A15-Lys-Gln-A18-Gln-Iva-Glu-Phe-Val-Arg-His-Leu-Leu-Asn-Lys-Aib-Thr-Arg-Gln-Arg-A35-NH2 wherein each symbol is as defined in the specification, and the treatment or prophylaxis of obesity, diabetes and the like using the peptide compound.
    Type: Application
    Filed: May 23, 2017
    Publication date: July 4, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Taiji ASAMI, Ayumu NIIDA
  • Patent number: 10336864
    Abstract: The present invention relates to a graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof (e.g., a graft copolymer (?-PGA-PAE) of poly(?-glutamic acid) (?-PGA) and phenylalanine ethyl ester (PAE)), an ionized graft copolymer of a poly(amino acid) or a salt thereof and a hydrophobic primary amine compound or a salt thereof, nanoparticles containing the ionized graft copolymer, and a production method thereof. The nanoparticles acquired in this way are useful as an adjuvant for producing a vaccine.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: July 2, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Mitsuhisa Yamano, Toshiaki Nagata, Hideki Saitoh
  • Patent number: 10335402
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: July 2, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Philip Mitchell, Martin Teall
  • Patent number: 10336833
    Abstract: Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: July 2, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kathleen Ann Elias, Gregory Landes, Shweta Singh, Wouter Korver, Andrew Walling Drake, Mary Haak-Frendscho, Gyorgy Pal Snell, Vinay Bhaskar
  • Publication number: 20190194628
    Abstract: The present disclosure relates to methods of producing Enterovirus C, e.g., for poliomyelitis vaccine production. In some embodiments, the methods include adding polysorbate to the cell culture medium during or prior to inoculation with the virus and/or culturing cells in a fixed bed bioreactor. Further provided herein is an Enterovirus C produced by the methods of production disclosed herein, as well as compositions, immunogenic compositions, and vaccines related thereto.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 27, 2019
    Applicants: Takeda Vaccines, Inc., Takeda Pharmaceutical Company Limited
    Inventors: Raman RAO, Tatsuki SATO, Kaori ODA, Kuniaki NAKAMURA, Takeshi NISHIHAMA
  • Patent number: 10328089
    Abstract: Disclosed are compounds of Formula 1, stereoisomers thereof and pharmaceutically acceptable salts of the compounds and stereoisomers, wherein R1 and R2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: June 25, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Zacharia Cheruvallath, John David Lawson, Christopher McBride
  • Patent number: 10329306
    Abstract: Disclosed is a crystalline polymorph 1-(1-methyl-1H-pyrazol-4-yl)-N-((1R,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1H-indole-3-carboxamide, Form G, and processes for making the same.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: June 25, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Yuxin Zhao
  • Patent number: 10323027
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: June 18, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
  • Patent number: 10323026
    Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 18, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shuhei Ikeda, Hideyuki Sugiyama, Jumpei Aida, Hidekazu Tokuhara, Tomohiro Okawa, Yuya Oguro, Minoru Nakamura, Masataka Murakami
  • Publication number: 20190169166
    Abstract: Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: August 9, 2017
    Publication date: June 6, 2019
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jun FUJIMOTO, Xin LIU, Osamu KURASAWA, Terufumi TAKAGI, Douglas Robert CARY, Hiroshi BANNO, Yasutomi ASANO, Takuto KOJIMA
  • Patent number: 10308643
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Masashi Toyofuku, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Kousuke Hidaka
  • Patent number: 10307414
    Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
  • Patent number: 10308605
    Abstract: A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug ther
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Kajino, Atsushi Hasuoka, Naoki Tarui, Terufumi Takagi